LiverLearning®: Liver Cell Biology in Hepatic Diseases SIG: DAMPs and New Receptor Signaling in Liver Disease

Gain a solid background on the mechanisms that activate and potentiate hepatic injury, inflammation and fibrosis through an in-depth presentation of the different yet related basic molecular mechanisms that underlie various types of hepatic damage.Melanie J. Scott Xiaoxia Li Nissiam Hay Yingzi Yang

LiverLearning®: Portal Hypertension SIG: Critical Review of Invasive Interventions in Patients with Portal Hypertension

Join international portal hypertension experts for a critical review of several invasive interventions performed in patients with the disease. This session will look at potential situations that may interfere with the accuracy and reproducibility of hepatic venous pressure gradient and portal pressure gradient measurements in the course of TIPS. It will also discuss recommendations for standardizing the procedure.

LiverLearning®: Pediatric Liver Disease SIG: Drug Induced Liver Injury in Children: Causes, Criteria, and Complications

As the number and type of drugs used to treat pediatric illnesses proliferate, and the push to make new drugs available for children gains speed, understanding how to recognize drug-induced liver injury is increasingly important for pediatric liver providers. This program will focus on challenges and opportunities associated with the diagnosis and management of DILI that are unique to the pediatric population. Clinical presentations include surreptitious elevation of serum aminotransferase levels, acute liver injury with or without acute liver failure, and chronic liver disease.Binita M.

LiverLearning®: Hepatotoxicity SIG: Drug-Induced Liver Injury Due to Chemotherapeutic Agents

A look at both traditional and new chemotherapeutic agents associated with liver injury will help attendees gain a working knowledge of agents that can cause liver injury, how the injury presents, and how to make the diagnosis. This program also offers new insight on the challenges for chemotherapeutic drug development, approval and post-marketing surveillance in the U.S.Jay H. Hoofnagle Jay H.

Subscribe to